Sling Therapeutics Overview

  • Year Founded
  • 2021

Year Founded

  • Status
  • Private

  • Employees
  • 10

Employees

  • Latest Deal Type
  • Early Stage VC

  • Investors
  • 3

Sling Therapeutics General Information

Description

Developer of oral small molecule linsitinib intended to bring additional treatment options to patients, as well as the ophthalmology, endocrinology, and rare disease communities. The company offers oral small molecules for the treatment of thyroid eye disease, enabling medical professionals to cure patients with these diseases.

Contact Information

Website
www.slingtx.com
Formerly Known As
Vasaragen
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 455 East Eisenhower Parkway
  • Suite 300 PMB 109
  • Ann Arbor, MI 48108
  • United States
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Life Sciences
Corporate Office
  • 455 East Eisenhower Parkway
  • Suite 300 PMB 109
  • Ann Arbor, MI 48108
  • United States

Sling Therapeutics Timeline

2022202320242025
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Sling Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Early Stage VC 20-Jan-2023 Completed Clinical Trials - Phase 2
2. Early Stage VC (Series A) 13-Jun-2022 Completed Clinical Trials - Phase 2
1. Accelerator/Incubator 01-Jan-2021 Completed Startup
To view Sling Therapeutics’s complete valuation and funding history, request access »

Sling Therapeutics Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Series A
Series A-1
To view Sling Therapeutics’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Request a free trial

Sling Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of oral small molecule linsitinib intended to bring additional treatment options to patients, as well as the o
Drug Discovery
Ann Arbor, MI
10 As of 2024

Ecublens, Switzerland
 

Cambridge, MA
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Sling Therapeutics Competitors (42)

One of Sling Therapeutics’s 42 competitors is Anokion, a Venture Capital-Backed company based in Ecublens, Switzerland.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Anokion Venture Capital-Backed Ecublens, Switzerland
AnTolRx Venture Capital-Backed Cambridge, MA
PHAXIAM Therapeutics Formerly VC-backed Lyon, France
Cristal Therapeutics Venture Capital-Backed Maastricht, Netherlands
Orchard Therapeutics Formerly VC-backed London, United Kingdom
You’re viewing 5 of 42 competitors. Get the full list »

Sling Therapeutics Patents

  • 1

    Total Documents Applications and Grants

  • Total Patents Families

  • 1

    Granted

  • Pending

  • Expiring in next 12 mo

Sling Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-11976074-B1 Crystalline salts of linsitinib Active 20-Jun-2023

Sling Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Sling Therapeutics Investors (3)

Investor Name Investor Type Holding Investor Since Participating Rounds
The Rise Fund Impact Investing Minority
TPG PE/Buyout Minority
Innovation Partnerships Venture Capital Minority
To view Sling Therapeutics’s complete investors history, request access »

Ready to get started?

Request a free trial

Sling Therapeutics FAQs

  • When was Sling Therapeutics founded?

    Sling Therapeutics was founded in 2021.

  • Where is Sling Therapeutics headquartered?

    Sling Therapeutics is headquartered in Ann Arbor, MI.

  • What is the size of Sling Therapeutics?

    Sling Therapeutics has 10 total employees.

  • What industry is Sling Therapeutics in?

    Sling Therapeutics’s primary industry is Drug Discovery.

  • Is Sling Therapeutics a private or public company?

    Sling Therapeutics is a Private company.

  • What is Sling Therapeutics’s current revenue?

    The current revenue for Sling Therapeutics is .

  • How much funding has Sling Therapeutics raised over time?

    Sling Therapeutics has raised $35M.

  • Who are Sling Therapeutics’s investors?

    The Rise Fund, TPG, and Innovation Partnerships have invested in Sling Therapeutics.

  • Who are Sling Therapeutics’s competitors?

    Anokion, AnTolRx, PHAXIAM Therapeutics, Cristal Therapeutics, and Orchard Therapeutics are some of the 42 competitors of Sling Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »